ITK and neoplasm: Interestingly, even after tumor relapse at day 56, animals that received ITK-KO CD19-CAR-T cells exhibited better control of the relapsed tumor, leading to significantly improved survival (Figure 6, H and I, and Supplemental Figure 6E).